Trial Profile
A study evaluating fibrosis progression and incidence of cirrhosis and hepatic decompensation in persons treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ERCHIVES
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017